IL-13 is essential to the late-phase response in allergic rhinitis

Satoko Miyahara, Nobuaki Miyahara, Shigeki Matsubara, Katsuyuki Takeda, Toshiyuki Koya, Erwin W. Gelfand

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background: The pathophysiology of the early- and late-phase nasal response to allergen challenge is not completely defined. Recent technical advances enable direct monitoring of these responses in mice. Objective: IL-13 is detected in the nasal membranes of both human beings and mice with allergic rhinitis, but its role in disease pathogenesis is unclear. We measured early and late nasal allergic responses after treatment with soluble IL-13Rα2-IgG fusion protein (sIL-13Rα2-Fc), and in IL-13-deficient mice (IL-13 -/-). Methods: IL-13 -/- mice (BALB/c background) and wild-type mice were sensitized to ovalbumin by intraperitoneal injection and then challenged intranasally with ovalbumin without sedation. The sIL-13Rα2-Fc or control human IgG was administered by intraperitoneal (i.p.) injection 24 hours and 1 hour before each ovalbumin challenge. Early nasal responses after the 4th ovalbumin challenge and late nasal responses 24 hours after the 6th ovalbumin challenge were assessed. Results: Sensitized/challenged wild-type mice treated with sIL-13Rα2-Fc or IL-13 -/- mice demonstrated significantly reduced late nasal responses in face of persistent nasal tissue eosinophilia; the early nasal response was little affected by targeting IL-13. Goblet cell hyperplasia was not detected in nasal membranes. Conclusion: The data indicate that IL-13 is a major contributor to the development of a late nasal response with little influence on the early response, and without affecting nasal eosinophilic inflammation. Inhibition of IL-13 may have an important therapeutic application in preventing the persistent nasal blockage in allergic rhinitis. Clinical implications: Current therapies for allergic rhinitis may not take into account the important differences in the pathophysiology of the early and late responses and the important role of IL-13 in sustaining chronic nasal congestion and obstruction.

Original languageEnglish
Pages (from-to)1110-1116
Number of pages7
JournalJournal of Allergy and Clinical Immunology
Volume118
Issue number5
DOIs
Publication statusPublished - Nov 2006
Externally publishedYes

Fingerprint

Interleukin-13
Rhinitis
Nose
Ovalbumin
Nasal Obstruction
Intraperitoneal Injections
Immunoglobulin G
Goblet Cells
Membranes
Eosinophilia
Allergens
Hyperplasia
Therapeutics
Inflammation

Keywords

  • Allergic rhinitis
  • early phase
  • IL-13
  • late phase
  • nasal resistance

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

IL-13 is essential to the late-phase response in allergic rhinitis. / Miyahara, Satoko; Miyahara, Nobuaki; Matsubara, Shigeki; Takeda, Katsuyuki; Koya, Toshiyuki; Gelfand, Erwin W.

In: Journal of Allergy and Clinical Immunology, Vol. 118, No. 5, 11.2006, p. 1110-1116.

Research output: Contribution to journalArticle

Miyahara, Satoko ; Miyahara, Nobuaki ; Matsubara, Shigeki ; Takeda, Katsuyuki ; Koya, Toshiyuki ; Gelfand, Erwin W. / IL-13 is essential to the late-phase response in allergic rhinitis. In: Journal of Allergy and Clinical Immunology. 2006 ; Vol. 118, No. 5. pp. 1110-1116.
@article{6417af1f002d4054bcdc92c4eccf87fd,
title = "IL-13 is essential to the late-phase response in allergic rhinitis",
abstract = "Background: The pathophysiology of the early- and late-phase nasal response to allergen challenge is not completely defined. Recent technical advances enable direct monitoring of these responses in mice. Objective: IL-13 is detected in the nasal membranes of both human beings and mice with allergic rhinitis, but its role in disease pathogenesis is unclear. We measured early and late nasal allergic responses after treatment with soluble IL-13Rα2-IgG fusion protein (sIL-13Rα2-Fc), and in IL-13-deficient mice (IL-13 -/-). Methods: IL-13 -/- mice (BALB/c background) and wild-type mice were sensitized to ovalbumin by intraperitoneal injection and then challenged intranasally with ovalbumin without sedation. The sIL-13Rα2-Fc or control human IgG was administered by intraperitoneal (i.p.) injection 24 hours and 1 hour before each ovalbumin challenge. Early nasal responses after the 4th ovalbumin challenge and late nasal responses 24 hours after the 6th ovalbumin challenge were assessed. Results: Sensitized/challenged wild-type mice treated with sIL-13Rα2-Fc or IL-13 -/- mice demonstrated significantly reduced late nasal responses in face of persistent nasal tissue eosinophilia; the early nasal response was little affected by targeting IL-13. Goblet cell hyperplasia was not detected in nasal membranes. Conclusion: The data indicate that IL-13 is a major contributor to the development of a late nasal response with little influence on the early response, and without affecting nasal eosinophilic inflammation. Inhibition of IL-13 may have an important therapeutic application in preventing the persistent nasal blockage in allergic rhinitis. Clinical implications: Current therapies for allergic rhinitis may not take into account the important differences in the pathophysiology of the early and late responses and the important role of IL-13 in sustaining chronic nasal congestion and obstruction.",
keywords = "Allergic rhinitis, early phase, IL-13, late phase, nasal resistance",
author = "Satoko Miyahara and Nobuaki Miyahara and Shigeki Matsubara and Katsuyuki Takeda and Toshiyuki Koya and Gelfand, {Erwin W.}",
year = "2006",
month = "11",
doi = "10.1016/j.jaci.2006.06.014",
language = "English",
volume = "118",
pages = "1110--1116",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - IL-13 is essential to the late-phase response in allergic rhinitis

AU - Miyahara, Satoko

AU - Miyahara, Nobuaki

AU - Matsubara, Shigeki

AU - Takeda, Katsuyuki

AU - Koya, Toshiyuki

AU - Gelfand, Erwin W.

PY - 2006/11

Y1 - 2006/11

N2 - Background: The pathophysiology of the early- and late-phase nasal response to allergen challenge is not completely defined. Recent technical advances enable direct monitoring of these responses in mice. Objective: IL-13 is detected in the nasal membranes of both human beings and mice with allergic rhinitis, but its role in disease pathogenesis is unclear. We measured early and late nasal allergic responses after treatment with soluble IL-13Rα2-IgG fusion protein (sIL-13Rα2-Fc), and in IL-13-deficient mice (IL-13 -/-). Methods: IL-13 -/- mice (BALB/c background) and wild-type mice were sensitized to ovalbumin by intraperitoneal injection and then challenged intranasally with ovalbumin without sedation. The sIL-13Rα2-Fc or control human IgG was administered by intraperitoneal (i.p.) injection 24 hours and 1 hour before each ovalbumin challenge. Early nasal responses after the 4th ovalbumin challenge and late nasal responses 24 hours after the 6th ovalbumin challenge were assessed. Results: Sensitized/challenged wild-type mice treated with sIL-13Rα2-Fc or IL-13 -/- mice demonstrated significantly reduced late nasal responses in face of persistent nasal tissue eosinophilia; the early nasal response was little affected by targeting IL-13. Goblet cell hyperplasia was not detected in nasal membranes. Conclusion: The data indicate that IL-13 is a major contributor to the development of a late nasal response with little influence on the early response, and without affecting nasal eosinophilic inflammation. Inhibition of IL-13 may have an important therapeutic application in preventing the persistent nasal blockage in allergic rhinitis. Clinical implications: Current therapies for allergic rhinitis may not take into account the important differences in the pathophysiology of the early and late responses and the important role of IL-13 in sustaining chronic nasal congestion and obstruction.

AB - Background: The pathophysiology of the early- and late-phase nasal response to allergen challenge is not completely defined. Recent technical advances enable direct monitoring of these responses in mice. Objective: IL-13 is detected in the nasal membranes of both human beings and mice with allergic rhinitis, but its role in disease pathogenesis is unclear. We measured early and late nasal allergic responses after treatment with soluble IL-13Rα2-IgG fusion protein (sIL-13Rα2-Fc), and in IL-13-deficient mice (IL-13 -/-). Methods: IL-13 -/- mice (BALB/c background) and wild-type mice were sensitized to ovalbumin by intraperitoneal injection and then challenged intranasally with ovalbumin without sedation. The sIL-13Rα2-Fc or control human IgG was administered by intraperitoneal (i.p.) injection 24 hours and 1 hour before each ovalbumin challenge. Early nasal responses after the 4th ovalbumin challenge and late nasal responses 24 hours after the 6th ovalbumin challenge were assessed. Results: Sensitized/challenged wild-type mice treated with sIL-13Rα2-Fc or IL-13 -/- mice demonstrated significantly reduced late nasal responses in face of persistent nasal tissue eosinophilia; the early nasal response was little affected by targeting IL-13. Goblet cell hyperplasia was not detected in nasal membranes. Conclusion: The data indicate that IL-13 is a major contributor to the development of a late nasal response with little influence on the early response, and without affecting nasal eosinophilic inflammation. Inhibition of IL-13 may have an important therapeutic application in preventing the persistent nasal blockage in allergic rhinitis. Clinical implications: Current therapies for allergic rhinitis may not take into account the important differences in the pathophysiology of the early and late responses and the important role of IL-13 in sustaining chronic nasal congestion and obstruction.

KW - Allergic rhinitis

KW - early phase

KW - IL-13

KW - late phase

KW - nasal resistance

UR - http://www.scopus.com/inward/record.url?scp=33750531068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750531068&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2006.06.014

DO - 10.1016/j.jaci.2006.06.014

M3 - Article

VL - 118

SP - 1110

EP - 1116

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 5

ER -